Fabry’s Disease Pipeline Analysis report covers more than 15S drugs currently in different phases of development. Fabry’s disease is a rare genetic disorder caused mostly in males than females due to the deficiency of the alpha-galactosidase A (a-Gal A) enzyme which causes a build-up of a type of fat, globotriaosylceramide (Gb3, or GL-3) in the body. It is also categorized as a type of lysosomal storage disorder. The disease affects skin, eyes, gastrointestinal system, kidney, heart, brain and nervous system among other body parts.
The report provides Fabry’s Disease treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Biosidus, Sanofi, Amicus Therapeutics, Inc., Protalix and Neuraltus Pharmaceuticals, Inc.among others.
Scope:
By Company
By Phase
By Molecule Type
By Region
By Route of Administration